Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HAT
MCID: HPR003
MIFTS: 49

Heparin-Induced Thrombocytopenia (HAT)

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Heparin-Induced Thrombocytopenia

About this section

MalaCards integrated aliases for Heparin-Induced Thrombocytopenia:

Name: Heparin-Induced Thrombocytopenia 54 60 74
Hit 54 60
Heparin-Induced Thrombocytopenia Type 2 60
Heparin-Associated Thrombocytopenia 60
Hat 60

Characteristics:

Orphanet epidemiological data:

60
heparin-induced thrombocytopenia
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 35 D69.5
UMLS via Orphanet 75 C0272285
Orphanet 60 ORPHA3325
UMLS 74 C0272285
Sources

Summaries for Heparin-Induced Thrombocytopenia

About this section
NIH Rare Diseases : 54 Heparin-induced thrombocytopenia (HIT) is an adverse reaction to the drug heparin resulting in an abnormally low amount of platelets (thrombocytopenia). HIT is usually an immune response which typically occurs 4-10 days after exposure to heparin; it can lead to serious complications and be life-threatening. This condition occurs in up to 5% of those who are exposed to heparin. Characteristic signs of HIT are a drop in platelet count of  greater than 50% and/or the formation of new blood clots during heparin therapy.  The first step of treatment is to discontinue and avoid all heparin products immediately. Often, affected individuals require another medicine to prevent blood clotting (anticoagulants).

MalaCards based summary : Heparin-Induced Thrombocytopenia, also known as hit, is related to thrombosis and catastrophic antiphospholipid syndrome. An important gene associated with Heparin-Induced Thrombocytopenia is F3 (Coagulation Factor III, Tissue Factor), and among its related pathways/superpathways are Collagen chain trimerization and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Heparin and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and b cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count),... more...

Sources

Related Diseases for Heparin-Induced Thrombocytopenia

About this section

Diseases related to Heparin-Induced Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 thrombosis 31.2 F10 F3 SERPINC1
2 catastrophic antiphospholipid syndrome 30.6 CD40LG F3
3 pulmonary embolism 30.4 F10 F3 SERPINC1
4 budd-chiari syndrome 30.3 F3 SERPINC1
5 endocarditis 30.3 FCGR2A SERPINC1
6 coronary thrombosis 30.3 F3 SERPINC1
7 thrombophilia due to thrombin defect 30.2 F10 F3 SERPINC1
8 disseminated intravascular coagulation 30.2 F3 SERPINC1
9 purpura 30.2 CD79A F3 SERPINC1
10 sagittal sinus thrombosis 30.1 F3 SERPINC1
11 antiphospholipid syndrome 30.0 CD40LG F10 F3 SERPINC1
12 marantic endocarditis 29.9 F3 SERPINC1
13 intracranial thrombosis 29.9 F3 SERPINC1
14 protein s deficiency 29.8 F3 SERPINC1
15 myocardial infarction 29.7 CD40LG F10 F3 SERPINC1
16 thrombocytosis 29.6 F3 SERPINC1
17 systemic lupus erythematosus 29.6 CD40LG CD79A F3 FCGR2A
18 arteries, anomalies of 29.5 F3 SERPINC1
19 thrombocytopenia 11.6
20 ischemia 10.4
21 acute myocardial infarction 10.3
22 essential thrombocythemia 10.3
23 paroxysmal nocturnal hemoglobinuria 10.3
24 thrombotic thrombocytopenic purpura 10.3
25 hemoglobinuria 10.3
26 polycythemia vera 10.2
27 polycythemia 10.2
28 rere-related disorders 10.2
29 bilateral massive adrenal hemorrhage 10.2
30 c1q nephropathy 10.2 CD40LG CD79A
31 immunoglobulin g deficiency 10.2 CD40LG CD79A
32 cryofibrinogenemia 10.2 CD40LG CD79A
33 immunoglobulin a deficiency 1 10.2 CD40LG CD79A
34 sporotrichosis 10.2 CD40LG CD79A
35 congenital syphilis 10.2 CD40LG CD79A
36 autoimmune disease 10.2
37 limb ischemia 10.2
38 transient global amnesia 10.2
39 myocarditis 10.2
40 lupus erythematosus 10.2
41 giant cell myocarditis 10.2
42 syphilis 10.2 CD40LG CD79A
43 secondary syphilis 10.2 CD40LG CD79A
44 immunodeficiency-centromeric instability-facial anomalies syndrome 1 10.2 CD40LG CD79A
45 ocular toxoplasmosis 10.2 CD40LG CD79A
46 toxoplasmosis 10.2 CD40LG CD79A
47 persistent generalized lymphadenopathy 10.2 CD40LG CD79A
48 immunodeficiency with hyper-igm, type 1 10.1 CD40LG CD79A
49 congenital toxoplasmosis 10.1 CD40LG CD79A
50 immunoglobulin alpha deficiency 10.1 CD40LG CD79A

Graphical network of the top 20 diseases related to Heparin-Induced Thrombocytopenia:



Diseases related to Heparin-Induced Thrombocytopenia
Sources

Symptoms & Phenotypes for Heparin-Induced Thrombocytopenia

About this section

MGI Mouse Phenotypes related to Heparin-Induced Thrombocytopenia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.35 CD40LG CD79A F3 FCGR2A SERPINC1
2 immune system MP:0005387 9.02 CD40LG CD79A F3 FCGR2A SERPINC1
Sources

Drugs & Therapeutics for Heparin-Induced Thrombocytopenia

About this section

Drugs for Heparin-Induced Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
2
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
3 Certoparin Approved, Investigational Phase 4
4
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
5
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
6
Fondaparinux Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104993-28-4
7
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 1 128270-60-0 16129704
8
Argatroban Approved, Investigational Phase 4,Phase 3,Phase 2 74863-84-6 152951
9
Nadroparin Approved, Investigational Phase 4
10
Desirudin Approved Phase 4,Phase 2,Phase 3 120993-53-5
11
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2
12
Lepirudin Approved Phase 4 120993-53-5, 138068-37-8 16132441
13
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
14
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
15
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
16 calcium heparin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Immunoglobulins Phase 4,Phase 3,Phase 1
18 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Heparin, Low-Molecular-Weight Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
20 Antibodies Phase 4,Phase 3,Phase 1
21 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Antithrombin III Phase 4,Phase 3,Phase 2,Phase 1
25 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Antithrombins Phase 4,Phase 3,Phase 2,Phase 1
27
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Immunologic Factors Phase 4,Phase 1
29 PENTA Phase 4,Phase 3,Phase 2,Phase 1
30 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
31 Hirudins Phase 4,Phase 3,Phase 2,Phase 1
32 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
33 Thromboplastin Phase 4,Phase 3,Phase 2
34 Liver Extracts Phase 4
35 Platelet Factor 4 Phase 4,Not Applicable
36
Bilirubin Phase 4 635-65-4, 69853-43-6 5280352 21252250
37 Coagulants Phase 4
38
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
39
tannic acid Approved Phase 3 1401-55-4
40
Rivaroxaban Approved Phase 3,Phase 2 366789-02-8
41
Ethanol Approved Phase 3 64-17-5 702
42
Sodium Citrate Approved, Investigational Phase 3 68-04-2
43
Creatine Approved, Investigational, Nutraceutical Phase 2, Phase 3 57-00-1 586
44 Kava Approved, Investigational, Nutraceutical Phase 2, Phase 3 9000-38-8
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
46 Dermatan Sulfate Phase 3
47 Anti-Infective Agents Phase 3
48 Central Nervous System Depressants Phase 3
49 Anti-Infective Agents, Local Phase 3
50 Pharmaceutical Solutions Phase 3

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 The HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Unknown status NCT02355873 Phase 4
3 Impact of Heparin on the Need for Mechanical Ventilation in Neonates Unknown status NCT00196469 Phase 4 heparin
4 Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Completed NCT00759083 Phase 4 bivalirudin
5 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
6 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
7 Nadroparin for the Initial Treatment of Pulmonary Thromboembolism Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
8 Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin Completed NCT00622648 Phase 4 Enoxaparin;Placebo
9 EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
10 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis Completed NCT00913133 Phase 4 Desirudin
11 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
12 Maintaining Patency in Implanted Port Catheters Recruiting NCT02354118 Phase 4
13 Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy Recruiting NCT01828697 Phase 4 Low dose nadroparin;Intermediate dose nadroparin;Low dose enoxaparin;Intermediate dose enoxaparin;Low dose dalteparin;Intermediate dose dalteparin;Fixed low dose tinzaparin;Intermediate dose tinzaparin
14 A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome Terminated NCT00787332 Phase 4 Desirudin or Argatroban®
15 Argatroban Versus Lepirudin in Critically Ill Patients Terminated NCT00798525 Phase 4 Argatroban;Lepirudin
16 Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion Terminated NCT01246011 Phase 4 Argatroban and warfarin
17 Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes Terminated NCT02923830 Phase 4 Saline-only catheter flush
18 Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) Withdrawn NCT00603824 Phase 4 fondaparinux;argatroban or lepirudin
19 Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study Unknown status NCT00474591 Phase 3 Fondaparinux
20 Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia Completed NCT00198588 Phase 3 argatroban
21 Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning) Completed NCT00043940 Phase 3 bivalirudin
22 Angiomax in Patients With HIT/HITTS Type II Undergoing CPB Completed NCT00079508 Phase 3 Angiomax (bivalirudin)
23 Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) Completed NCT00073580 Phase 3 Angiomax (bivalirudin) anticoagulant
24 Heparin 100U/L for Prevention of PVC Complications Completed NCT01131754 Phase 3
25 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed NCT00182143 Phase 3 LMWH (Fragmin, dalteparin);Unfractionated Heparin
26 The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients Completed NCT00531843 Phase 2, Phase 3 fondaparinux sodium
27 PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot Completed NCT01274637 Phase 3 Dalteparin Sodium
28 Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery Completed NCT00329433 Phase 2, Phase 3 Desirudin (Iprivask™);Heparin
29 A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries Completed NCT02368314 Phase 3 Sodium Enoxaparine
30 Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT) Recruiting NCT03147638 Phase 3 Warfarin, NOAC
31 An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects With Acute HIT Not yet recruiting NCT03809481 Phase 3 Danaparoid Sodium;Argatroban
32 Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients Not yet recruiting NCT03083184 Phase 3 Ethanol;enoxaparin
33 Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients Suspended NCT02271295 Phase 3 Enoxaparine
34 Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Terminated NCT01598168 Phase 3 Rivaroxaban
35 Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma Terminated NCT01773083 Phase 3 unfractionated heparin;placebo
36 Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II Completed NCT00861692 Phase 2 argatroban
37 ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial Completed NCT00839826 Phase 2 Rivaroxaban (BAY59-7939);Enoxaparin
38 Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Completed NCT02334007 Phase 1, Phase 2 LMWH: Dalteparin
39 Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) Recruiting NCT03594045 Phase 2 Apixaban
40 Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer Recruiting NCT03254511 Phase 2 Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable;Chemotherapeutic Combinations
41 Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin Recruiting NCT02501434 Phase 2 Continuous Low-Dose IV Unfractionated Heparin Infusion
42 Heparin Anticoagulation in Septic Shock Recruiting NCT03378466 Phase 2 Unfractionated heparin
43 Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial Recruiting NCT03003390 Phase 2 Enoxaparin
44 Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) Terminated NCT00673439 Phase 2 fondaparinux;warfarin
45 Heparin-Induced Thrombocytopenia Score Card Study Completed NCT00489437 Phase 1
46 Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Completed NCT00412464 Phase 1 Fondaparinux
47 Bivalirudin vs Heparin in ECMO Patients Not yet recruiting NCT03707418 Phase 1 Heparin Sodium;Bivalirudin Injection [Angiomax]
48 Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) Unknown status NCT00946400
49 A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients Unknown status NCT00198575
50 Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure Unknown status NCT01102790

Search NIH Clinical Center for Heparin-Induced Thrombocytopenia

Sources

Genetic Tests for Heparin-Induced Thrombocytopenia

About this section
Sources

Anatomical Context for Heparin-Induced Thrombocytopenia

About this section

MalaCards organs/tissues related to Heparin-Induced Thrombocytopenia:

42
Testes, Heart, B Cells, Liver, Brain, Skin, Kidney
Sources

Publications for Heparin-Induced Thrombocytopenia

About this section

Articles related to Heparin-Induced Thrombocytopenia:

(show top 50) (show all 4608)
# Title Authors Year
1
Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? ( 30725301 )
2019
2
Post-traumatic stress disorder and depression symptoms of adolescents survived from a seriously-hit area in China: A 3-year follow-up study. ( 30677716 )
2019
3
Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Upper Limb: Double Hit/Double Expressor with CNS Involvement: From Hospice to Remission. ( 30881709 )
2019
4
A double hit preeclampsia model results in sex-specific growth restriction patterns. ( 30683649 )
2019
5
Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. ( 30850560 )
2019
6
Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. ( 30478722 )
2019
7
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia. ( 30582672 )
2019
8
Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia. ( 30612329 )
2019
9
An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. ( 30640980 )
2019
10
Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experience. ( 30656269 )
2019
11
Successful Use of Cangrelor and Heparin for Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia and End-Stage Renal Disease: A Case Report. ( 30688681 )
2019
12
A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. ( 30693813 )
2019
13
False-Negative Platelet Factor 4 Antibodies and Serotonin Release Assay and the Utility of Repeat Testing in the Diagnosis of Heparin-Induced Thrombocytopenia and Thrombosis. ( 30729049 )
2019
14
Heparin-Induced Thrombocytopenia: Finding the Needle in the Haystack. ( 30768506 )
2019
15
High-dose Intravenous Immunoglobulin to Treat Spontaneous Heparin-induced Thrombocytopenia Syndrome. ( 30773806 )
2019
16
Development of an algorithm for the systematic evaluation of patients with suspected heparin-induced thrombocytopenia. ( 30790161 )
2019
17
Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia. ( 30828164 )
2019
18
Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay. ( 30850576 )
2019
19
Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes. ( 30854309 )
2019
20
Routine monitoring for heparin-induced thrombocytopenia following lower limb arthroplasty: Is it necessary? A prospective study in a UK district general hospital. ( 30878232 )
2019
21
Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. ( 30899022 )
2019
22
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. ( 30903805 )
2019
23
Mesenteric Ischemia Caused by Heparin-induced Thrombocytopenia: A Case Report. ( 30911456 )
2019
24
Heparin-Induced Thrombocytopenia in Infants after Heart Surgery. ( 29605959 )
2019
25
Fragment-based discovery of a qualified hit targeting the Latency-associated Nuclear Antigen of the oncogenic Kaposi's Sarcoma-associated Herpesvirus/Human Herpesvirus 8. ( 30888817 )
2019
26
Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma. ( 30613837 )
2019
27
Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. ( 30809101 )
2019
28
A case of 'resistant' thrombus: all you can hit in very late stent thrombosis. ( 30865136 )
2019
29
In Search of the Second Hit in Pulmonary Arterial Hypertension. ( 30605416 )
2019
30
HIT.WATER scheme: An integrated LCA-based decision-support platform for evaluation of wastewater discharge limits. ( 30577134 )
2019
31
Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors. ( 30368131 )
2019
32
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. ( 30774775 )
2019
33
A two-hit story: Seizures and genetic mutation interaction sets phenotype severity in SCN1A epilepsies. ( 30659983 )
2019
34
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). ( 29419530 )
2019
35
Global gene expression of histologically normal primary skin cells from BCNS subjects reveals "single-hit" effects that are influenced by rapamycin. ( 30858923 )
2019
36
FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation. ( 30860382 )
2019
37
Multi-hit early life adversity affects gut microbiota, brain and behavior in a sex-dependent manner. ( 30872090 )
2019
38
Corrigendum to "From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4" [Ejmech 154 (2018) 44-59]. ( 30904781 )
2019
39
Three is Better than One: An Improved Multiple Hit Model of Primary Graft Dysfunction. ( 30908931 )
2019
40
Reply to:' Bystander hit by leakage current from S-ICD. ( 30910508 )
2019
41
Radiation: a poly-traumatic hit leading to multi-organ injury. ( 30911370 )
2019
42
Prenatal two-hit stress affects maternal and offspring pregnancy outcomes and uterine gene expression in rats: match or mismatch? ( 30084951 )
2019
43
Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure. ( 30576906 )
2019
44
'Ridiculous' salary threshold could hit OVs. ( 30606848 )
2019
45
Huntington Disease's Glial Progenitor Cells Hit the Pause Button in the Mouse Brain. ( 30609397 )
2019
46
Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters. ( 30624935 )
2019
47
Syrian refugees hit by heavy rains. ( 30670177 )
2019
48
Generation of Quality Hit Matter for Successful Drug Discovery Projects. ( 30678174 )
2019
49
Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening. ( 30679614 )
2019
50
From the Brontës to J.K. Rowling and Beyond - Have We Hit a Wall? The Status of Women Authors. ( 30683597 )
2019
Sources

Variations for Heparin-Induced Thrombocytopenia

About this section
Sources

Expression for Heparin-Induced Thrombocytopenia

About this section
Search GEO for disease gene expression data for Heparin-Induced Thrombocytopenia.
Sources

Pathways for Heparin-Induced Thrombocytopenia

About this section

Pathways related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Collagen chain trimerization 67
Show member pathways
 12.15 F10 F3 SERPINC1
2
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.39 CD79A FCGR2A
3
Formation of Fibrin Clot (Clotting Cascade) 67
Show member pathways
 11.33 F10 F3 SERPINC1
4
Complement and coagulation cascades 38 1
10.94 F10 F3 SERPINC1
5
Primary immunodeficiency 38
10.72 CD40LG CD79A
Sources

GO Terms for Heparin-Induced Thrombocytopenia

About this section

Cellular components related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.43 CD40LG CD79A F10 F3 FCGR2A SERPINC1
2 intrinsic component of external side of plasma membrane GO:0031233 8.62 F10 F3

Biological processes related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.33 F10 F3 SERPINC1
2 B cell differentiation GO:0030183 9.32 CD40LG CD79A
3 B cell proliferation GO:0042100 9.26 CD40LG CD79A
4 blood coagulation, extrinsic pathway GO:0007598 8.96 F10 F3
5 hemostasis GO:0007599 8.8 F10 F3 SERPINC1

Molecular functions related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 8.96 F10 F3
2 protease binding GO:0002020 8.62 F3 SERPINC1
Sources

Sources for Heparin-Induced Thrombocytopenia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....